Should We Use Dialyzable β-Blockers in Hemodialysis?

dc.creator	Georgianos P.I., Eleftheriadis T., Liakopoulos V.	en
dc.date.accessioned	2023-01-31T07:40:45Z
dc.date.available	2023-01-31T07:40:45Z
dc.date.issued	2022
dc.identifier	10.1016/j.xkme.2022.100468
dc.identifier.issn	25900595
dc.identifier.uri	http://hdl.handle.net/11615/72144
dc.description.abstract	[No abstract available]	en
dc.language.iso	en	en
dc.source	Kidney Medicine	en
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129493086&doi=10.1016%2fj.xkme.2022.100468&partnerID=40&md5=882945146cc7b7633c1cb99a3b9efce5
dc.subject	antihypertensive agent	en
dc.subject	atenolol	en
dc.subject	beta adrenergic receptor blocking agent	en
dc.subject	bisoprolol	en
dc.subject	lisinopril	en
dc.subject	blood pressure	en
dc.subject	cell death	en
dc.subject	echocardiography	en
dc.subject	Editorial	en
dc.subject	heart arrest	en
dc.subject	hemodialysis	en
dc.subject	human	en
dc.subject	hypotension	en
dc.subject	mortality	en
dc.subject	proportional hazards model	en
dc.subject	retrospective study	en
dc.subject	Elsevier Inc.	en
dc.title	Should We Use Dialyzable β-Blockers in Hemodialysis?	en
dc.type	other	en

Files in this item

Files	Size	Format	View
There are no files associated with this item.